Why the study?
To test the hypothesis that serum IL-18 and hs-CRP can serve as markers of chronic low-grade inflammation more in type 2 diabetes than in obesity per se.
Serum IL-18 and hs-CRP are elevated in patients with type 2 diabetes and obesity, suggesting their utility as markers for chronic low-grade inflammation.
May support hs-CRP/IL-18 as inflammation markers in diabetic obesity; hypothesis-generating and requires prospective validation.
Background: Both diabetes and obesity are associated with chronic low-grade inflammation. IL-18 is a cytokine that stimulates various cell types and has pleiotropic functions. It is elevated in obesity, metabolic syndrome and type 2 diabetes (T2D). Aim of study: to test the hypothesis that serum level of IL-18 and high sensitive C-reactive protein can be used as markers for presence of chronic low-grade inflammation in type 2 diabetes more than in obesity per se. Subjects and methods: The study recruited 80 subjects. They comprised 20 diabetic obese cases (DM-OB group), 20 diabetic non-obese cases (DM-NOB group), : 20 non-diabetic obese cases (NDM-OB group) and 20 non-diabetic non-obese subjects (NDM-NOB group). All participants were submitted to careful history taking, through clinical investigations and laboratory assessment Results: hs-CRP was significantly highest in DMOB group (3.4±0.5 mg/dl) followed by NDM-OB group (2.9±0.4 mg/dl) followed by DM-NOB group (2.3±0.3 mg/dl) and least in NDM-NOB (0.8±0.3 mg/dl). Also, it was found that serum IL-18 was significantly highest in DMOB group (397.8±33.9 pg/mL) followed by NDM-OB (368.8±26.7 pg/mL) group followed by DM-NOB group (335.9±18.4 pg/mL) and least in NDM-NOB group (281.1±22.9 pg/mL). Serum IL-18 levels are directly correlated with BMI, waist circumference, hip circumference and waist/hip ratio in all the studied groups and with HbA1c in the diabetic groups. Conclusions: Serum IL-18 and hs-CRP are related to diabetes and obesity. They are associated with dyslipidemia, poor glycemic control, insulin resistance and impaired liver and renal functions.
No takes yet. Share an insight, caveat, or question.
Kamel et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: